Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent

DSpace/Manakin Repository

Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent

Citable link to this page


Title: Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
Author: Pantziarka, Pan; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vidula; Sukhatme, Vikas P

Note: Order does not necessarily reflect citation order of authors.

Citation: Pantziarka, Pan, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, and Vikas P Sukhatme. 2014. “Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent.” ecancermedicalscience 8 (1): 443. doi:10.3332/ecancer.2014.443.
Full Text & Related Files:
Abstract: Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with other drugs are discussed in the Appendix.
Published Version: doi:10.3332/ecancer.2014.443
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search